• CH 223191 and MEHP: Interpreting AhR Evidence

  2026-10-14

  A 2024 mouse ovarian follicle study used CH223191 to test whether aryl hydrocarbon receptor signaling contributes to mono(2-ethylhexyl) phthalate toxicity. The findings support functional involvement of AhR in altered follicle growth, estrogen production, and estrogen-responsive gene expression, while leaving direct receptor binding, pathway exclusivity, human relevance, and commercial-material equivalence unresolved.

• ALDH2 Activators in Myocardial Ischemia

  2026-10-14

  A 2025 ACS Medicinal Chemistry Letters study reports triazole compounds that activate ALDH2 and protect against myocardial ischemia–reperfusion injury in mice. The findings support a preclinical proof of concept, but they do not establish human efficacy, safety, or clinical applicability.

• AP20187: Evidence, Scope, and Applicability

  2026-10-13

  AP20187 is described as a chemical inducer of dimerization for engineered signaling systems. The supplied evidence supports a conditional, construct-dependent research concept, but does not establish broad pathway specificity, clinical utility, or a connection to the 14-3-3 mechanisms reported in the cited dissertation.

• KDM4A and Mesothelioma: Preclinical Evidence

  2026-10-13

  A 2021 study identified elevated KDM4A expression and functional dependence in malignant pleural mesothelioma models, but the evidence remains preclinical and does not establish clinical benefit or validate any specific commercial product.

• ddPCR and saRNA: What the Study Shows

  2026-10-12

  Casmil, Huang and Blakney evaluated multiplex droplet digital PCR as an absolute, two-region assay for assessing long self-amplifying RNA and measuring genomic versus subgenomic RNA in mammalian cells. Their findings support ddPCR as a useful analytical framework, while also showing that reverse-transcription format and assumptions about transcript integrity materially affect the estimates.

• What the PLpro Comparison Shows—and Leaves Open

  2026-10-12

  A 2023 Journal of Biological Chemistry study supports a context-dependent role for SARS-CoV-2 PLpro in regulating ER-associated proteins, but its cellular comparisons do not establish how broadly these effects apply during infection or in human disease.

• Hypoxia and Immunometabolism: Review and Limits

  2026-10-11

  A source-grounded overview of Wu et al.’s 2025 review on how tumor hypoxia and immune metabolism interact, what the review concludes, and why its conceptual findings should not be interpreted as evidence for Dovitinib efficacy.

• Eltanexor, XPO1, and Colorectal Cancer Prevention

  2026-10-10

  A 2024 bioRxiv preprint reports that XPO1 inhibition with Eltanexor reduces colorectal cancer-related signaling through effects on Wnt/β-catenin activity, COX-2 expression, and FoxO3a nuclear retention. In an Apcmin/+ mouse model, treatment was associated with lower tumor burden and smaller tumors, but the findings remain pre-peer-review and require validation before clinical conclusions can be drawn.

• FLT3–TAZ Signaling and Drug Resistance in BP-CML

  2026-10-09

  Shin et al. reposition FLT3 as a prognostic marker and therapeutic vulnerability in blast phase chronic myeloid leukemia, linking it to a JAK–STAT3–TAZ–TEAD–CD36 signaling axis that supports resistance to BCR::ABL1 tyrosine kinase inhibitors. The study is notable for integrating engineered cell models, patient samples, multi-omics analyses, and xenograft evidence, while also defining important boundaries between preclinical findings and clinical applicability.

• BFH772 VEGFR2 Inhibitor: Product Overview

  2026-10-09

  BFH772 is a supplier-listed small-molecule VEGFR2 inhibitor for conceptual research on VEGFR2 signaling and angiogenesis. No matched paper evidence was supplied, so product claims are not independently validated here.

• Wortmannin in PI3K Signaling Research

  2026-10-08

  A source-grounded overview of Wortmannin as a research tool for studying PI3K signaling, ferroptosis, autophagy, apoptosis, and cancer biology, with emphasis on evidence quality, pharmacological limitations, and the 2026 hepatocellular carcinoma study.

• SARS-CoV-2 PLpro and ER Protein Regulation

  2026-10-08

  Yang and colleagues show that membrane-anchored SARS-CoV-2 papain-like protease can regulate endoplasmic-reticulum proteins through both deubiquitination and proteolytic cleavage. The study distinguishes substrate-specific effects on INSIG-1, SREBP-1, and SREBP-2, expanding the view of PLpro beyond viral polyprotein processing and innate-immune antagonism.

• Shenqi Fuzheng, SRC/PI3K/AKT, and Glioma

  2026-10-07

  This study combines network pharmacology with cell-based and mouse-model evidence to investigate how Shenqi Fuzheng injection may affect glioma proliferation and migration. Its central contribution is the identification of SRC/PI3K/AKT signaling as a candidate mechanistic axis, while the experimental findings support—but do not by themselves prove—a causal, pathway-exclusive explanation.

• MK 0893 and the Extra-Helical GCGR Binding Site

  2026-10-07

  Jazayeri and colleagues reported a 2.5 Å structure showing that MK-0893 binds an unexpected allosteric pocket outside the seven-transmembrane bundle of the glucagon receptor. The study connects this site to restriction of TM6 movement, providing a structural framework for interpreting glucagon receptor antagonist pharmacology and future type 2 diabetes research.

• 1-Myristoylglycerophosphocholine: Evidence and Limits

  2026-10-06

  1-myristoylglycerophosphocholine, also called 14:0 Lyso-PC, is a defined lysophosphatidylcholine species used in lipid signaling research. A 2024 Respiratory Research study linked LysoPC accumulation from injured alveolar type II epithelial cells with fibroblast activation and experimental pulmonary fibrosis, while implicating an HMGCS2–PPARα–CPT1A/CPT2 pathway. However, the study examined LysoPCs as a class rather than establishing that 14:0 Lyso-PC alone drives the reported effects. This overview compares the evidence, identifies conceptual applications in lipid signaling pathway analysis and smooth muscle research, and defines important limits on interpretation.

8150 records 1/544 page Next 12345 下5页 Last page